Selective serotonin reuptake inhibitor-induced serotonin syndrome: Review

Journal of Clinical Psychopharmacology

Volumn 17, Issue 3, 1997, Pages 208-221

  Lane, Roger ^a   Baldwin, David ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BUSPIRONE; CHLORPROMAZINE; CLOMIPRAMINE; CYPROHEPTADINE; DEXTROMETHORPHAN; DIHYDROERGOTAMINE; FLUOXETINE; LITHIUM; METHYSERGIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORFLUOXETINE; NYQUIL; OPIATE AGONIST; PAROXETINE; PENTAZOCINE; PETHIDINE; PHENOTHIAZINE DERIVATIVE; PROPRANOLOL; SELEGILINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRAZODONE; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTONOMIC NEUROPATHY; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG WITHDRAWAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROMUSCULAR DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIDEPRESSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; NEUROMUSCULAR DISEASES; SEROTONIN UPTAKE INHIBITORS; SYNDROME;

EID: 0030984995     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199706000-00012     Document Type: Review

References (149)

1. Preskorn SH. Clinical pharmacology of serotonin selective reuptake inhibitors. Caddo, OK: Professional Communications, Inc., 1996.
2. Lejoyeux M, Ades J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 1994;2:132-43.
3. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148: 705-13.
4. Dursun SM, Burke JG, Reveley MA. Toxic serotonin syndrome or extrapyramidal side effects? Br J Psychiatry 1995;166:401-2.
5. Radomski JW, Dursun SM, Reveley MA. Toxic serotonin syndrome (TSS): an update and revised diagnostic criteria [abstract]. J Psychopharmacol 1995;9[suppl 2]:A21.
6. Lejoyeux M, Fineyre F, Ades J. The serotonin syndrome. Am J Psychiatry 1992;149:1410-1.
7. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal [letter]. Lancet 1988;2:850-1.
8. Feighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51:222-5.
9. Beasley CM, Masica DN, Heiligenstein JH, Wheaden DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacology 1993;13:312-20.
10. Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994;14: 144-5.
11. Bhatara VS, Bandettini F. Serotonin syndrome and drug interactions. Clin Pharmacol Ther 1993;1:84-8.
12. Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994;28:732-5.
13. Corkeron MA. Serotonin syndrome - a potentially fatal complication of antidepressant therapy. Med J Aust 1995;163:481-2.
14. Chiang WK, Smilksen MJ. Fluoxetine-monoamine oxidase inhibitor interaction. Vet Hum Toxicol 1989;31:369.
15. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994;24:983-5.
16. Power AC, Cowen PJ. Fluoxetine and suicidal behavior: some clinical and theoretical aspects of a controversy. Br J Psychiatry 1992;161:735-41.
17. Graham PM, Potter JM, Paterson J. Combination monoamine oxidase inhibitor/tricyclic antidepressant interaction [letter]. Lancet 1988;2(8295):440.
18. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between and amine and oxidase inhibitors and amine re-uptake inhibitors. Psychol Med 1983;13:735-49.
19. Salama AA, Shafey M. A case of severe lithium toxicity induce by combined fluoxetine and lithium carbonate [letter]. Am J Psychiatry 1989;146:278.
20. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium [letter]. Am J Psychiatry 1989;146:1515.
21. Evans AM, Marwik P. Fluvoxamine and lithium: an unusual interaction [letter]. Br J Psychiatry 1990;156:286.
22. Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium [letter]. Am J Psychiatry 1993;150:1565.
23. Shah AK, McCloskey O. Case report: acute confusional state secondary to a combination of fluoxetine and lithium. Int J Geriatr Psychiatry 1992;7:687-8.
24. Ohman R, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry 1993;26:263-4.
25. Committee on Safety of Medicines. Fluvoxamine and fluoxetine-interaction with monoamine oxidase inhibitors lithium and tryptophan. Current Problems 1989;26(May):2.
26. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986;21:1067-71.
27. Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone [letter]. Can J Psychiatry 1995;40:428-9.
28. Reeves R. Serotonin syndrome produced by paroxetine and low dose trazodone. Psychosomatics 1995;36:159-60.
29. Dursun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993;342:442-3.
30. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-8.
31. Skop BP, Finkelstein JA, Maretti TR, Magoon MR, Brown TM. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy. Am J Emerg Med 1994;12:642-4.
32. Mills KC. Serotonin syndrome. Am Fam Physician 1995;52: 1475-82.
33. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960; 10:1076-8.
34. Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 1969;7:83-8.
35. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963;1:70-81.
36. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment; a reevaluation. J Clin Psychopharmacol 1981;1:264-81.
37. Ciprian-Ollivier J, Cetkovich-Bakmas M, Albin J, Vazquez G. SSRI, L-tryptophan and serotonin syndrome. Experience with 75 patients. Eur Neuropsychopharmacol 1996;6[suppl 3]:143.
38. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-5.
39. Hopwood SE, Bogle S, Wildgust HJ. The combination of fluoxetine and lithium in clinical practice. Int Clin Psychopharmacol 1993;8:311-3.
40. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991;83:188-92.
41. Dinan TG. Lithium augmentation in sertraline resistant depression: a preliminary dose response study. Acta Psychiatr Scand 1993;88:300-1.
42. Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol 1996;16:130-4.
43. Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994; 28:405-6.
44. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol 1995; 15:106-9.
45. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data, J Clin Psychiatry 1996;57:257-64.
46. Joffe RT, Bakish D. Combined SSRI - moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-5.
47. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome. Ann Pharmacother 1996;30:191-2.
48. Tanner FC, Boulanger CM, Luscher TF. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost 1993;19:167-75.
49. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994;120:227-37.
50. Cowen PJ, McCance SL, Ware CJ, Cohen PR, Chalmers JS, Julier DL. Lithium in tricyclic-resistant depression, correlation of increased 5-HT function with clinical outcome. Br J Psychiatry 1991;159:341-6.
51. Schou M. Lithium and treatment-resistant depression: a review. Lithium 1990;1:3-8.
52. Hadley A, Cason MP. Mania resulting from lithium-fluoxetine combination. Am J Psychiatry 1989;146:1637-8.
53. Hawley CJ, Roberts AG, Baldwin DS. Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol 1994;9:31-3.
54. Wilner KD, Lazar JD, Von Deutsch DA, Apseloff G, Gerber N. The effects of sertraline on steady state lithium levels and renal clearance in man [abstract]. Biol Psychiatry 1991;29:354S.
55. Gram LF, Hansen MG, Sindrup SH, BrÍsen K, Poulsen JH, AaesJorgensen T, Overo KF. Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993; 15:18-24.
56. Hendricks B, Flores M. A controlled pilot study of the combination of fluvoxamine and lithium. Curr Ther Res 1991;49:106-10.
57. Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone [letter]. Psychosomatics 1992;33:235-6.
58. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;525:217-20.
59. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
60. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-12.
61. George T, Godelski LS. Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry 1996;39:383-6.
62. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995;17:333-5.
63. Marino MR, Langenbacher M, Ulderman HD. Interaction of nefazodone and fluoxetine [abstract]. Clin Pharmacol Ther 1996, 59:180.
64. Nierenberg AA, Alder LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia Am J Psychiatry 1994;151:1069-72.
65. Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 1992;215:153-60.
66. Sprouse JS, Bradberry CW, Roth RH, Aghajanian GK. 3,4-methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. Eur J Pharmacol 1990;178:313-20.
67. Randall T. Ecstasy-fueled "rave" parties become dances of death for English youths. JAMA 1992;268:1505-6.
68. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA (ecstasy). JAMA 1987;258:780-1.
69. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B. Ecstasy, 3-4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia [comment]. J R Soc Med 1991;84:371.
70. Campkin NTA, Davies UM. Another death from ecstasy [letter, comment]. J R Soc Med 1992;85:61.
71. Screaton GR, Singer M, Cairns HS, Thrasher A, Samer M, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 1992;339:677-8.
72. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340: 384-7.
73. Dowling GP, McDonough ET, Bosi RO. "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA [comment]. JAMA 1987;257:1615-7.
74. Kaskey GB. Possible interaction between MAOI and "ecstasy" [letter]. Am J Psychiatry 1992;149:411.
75. Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol 1987;25:159.
76. Lenzi A, Raffaelli S, Marazziti D. Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage. Pharmacopsychiatry 1993;26:100-1.
77. Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994;23:1371-499.
78. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991; 11:224-5.
79. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am J Hosp Pharm 1994;51:2279-81.
80. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? J Clin Psychiatry 1995;56:30-4.
81. Kreider MS, Bushnell WD, Oakes R, Wheadon DE. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. J Clin Psychiatry 1995;56:142-5.
82. Lane R, Fischler B. The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 1995;3:171-80.
83. Preskorn S, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
84. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker AT. The role of cytochrome P450 2D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-3.
85. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome [letter]. Am J Psychiatry 1993;150:837.
86. Bhatara V. Venlafaxine fluoxetine interaction? Curr Affect Illness 1994;13:14.
87. Nijhawan PK, Katz G, Winter S. Psychiatric illness and serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission. Crit Care Med 1996;24:1086-9.
88. Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline [letter]. Can J Psychiatry 1990;35:571.
89. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992;26:1300.
90. Montastruc JL, Charnontin B, Senard JM, Tran MA, Rascol O, Llau ME, Rascol A. Pseudophaeochromocytoma in parkinsonian patients treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341:555.
91. Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline [letter]. Can J Psychiatry 1990;35:571-2.
92. Baldessarini RJ, Cedarbaum JM, Schleifer LS. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990:384-435, 463-484.
93. Delini-Stula A, Mikkelsen H. Risk of 5-HT syndrome after co-administration of moclobemide (RIMA) and selective 5-HT re-uptake inhibitors (SSRI) - analysis of cases. Eur Neuropsychopharmacol 1993;3:337-8.
94. Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol 1993;7:167-80.
95. Wallnofer A, Guentert TW, Eckernas SA, Dingemanse J. Moclobemide and fluvoxamine coadministration: a prospective study in healthy volunteers to investigate the potential development of a "serotonin syndrome." Hum Psychopharmacol 1995; 10:25-32.
96. Dingemanse J. Pharmacological interactions with reversible MAOIs and clinical relevance. Eur Neuropsychopharmacol 1993; 3:239-41.
97. Hawley CJ, Pattinson HA, Ratnam S. A preliminary study of combined therapy with moclobemide and SSRIs. J Psychopharmacol 1995;9[suppl 3]:87.
98. Spigset O, Mjorndal T, Lovheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306:248.
99. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citaloprarn or moclobemide-clomipramine overdoses [letter]. Lancet 1993; 342:1419.
100. Sleight AJ, Marsden CA, Martin KF, Pallfreyman MG. Relationship between extracellular 5-hydroxytryptamine and behavior following monoamine oxidase inhibition and L-tryptophan. Br J Pharmacol 1988;93:303-10.
101. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 1992;106:S6-S14.
102. Fitton A, Foulds D, Goa KL. Moclobemide - a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-96.
103. Boyd IW. Hypertension with moclobemide [letter]. Lancet 1995; 346:1498.
104. Coulter DM, Pillans PI. Hypertension with moclobemide. Lancet 1995;346:1032.
105. Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine with pentazocine. Am J Psychiatry 1990; 147:949-50.
106. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol 1981;1:319-21.
107. Palmer H. Potentiation of pethidine. BMJ 1960;2:944.
108. Vigran IM. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA 1964;187:163-4.
109. Shee JC. Dangerous potentiation of pethidine by iproniazid, and its treatment. BMJ 1960;2:507-9.
110. Reid NCRW. Pethidine and phenelzine. BMJ 1962;1:408.
111. Taylor DC. Alarming reaction to pethidine in patients on phenelzine. Lancet 1962;2:401-2.
112. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 1955; 42:417-24.
113. Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. BMJ 1958;1070-2.
114. Rosenblatt JE, Rosenblatt NC. Clinical pharmacology online. Curr Affect Disord 1996;15:18.
115. Kamei J, Mori T, Igarashi H, Kasuya Y. Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs. Res Commun Chem Pathol Pharmacol 1992;78:371-4.
116. Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid [letter]. N Engl J Med 1988;319:1671.
117. Rivers N, Horner B. Possible lethal interaction between Nardil and dextromethorphan [letter]. Can Med Assoc J 1970;103:85.
118. Sauter D, Macneil P, Weinstein E, et al. Phenelzine sulfate-dextromethorphan interaction: a case report. Vet Hum Toxicol 1991;33:365.
119. Achamallah NS. Visual hallucinations after combining fluoxetine and dextromethorphan [letter]. Am J Psychiatry 1992;149: 1406.
120. Harvey AT, Burke M. Serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1995;13:605-6.
121. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16[suppl 2]:37S-53S.
122. Leung M, Ong M. Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache 1995; 35:488-9.
123. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia (in press).
124. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23.
125. Physicians' desk reference. 49th ed. Imitrex injection (sumatriptan succinate). Montvale, NJ: Medical Economics Data Production Company, 1995:855-8.
126. Susman VL, Addonizio G. Reinduction of neuroleptic malignant syndrome by lithium. J Clin Psychopharmacol 1987;7: 339-41.
127. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990;28:518-21.
128. Price J, Waller P, Wood S, et al. Safety of fluoxetine: comparison with fluvoxamine. Pharmacoepidemiol Drug Saf 1992;1: 111-7.
129. Nimmo SM, Kennedy BW, Tullet WM, Blyth AS, Dougall JR. Drug induced hyperthermia. Anaesthesia 1993;48:892-5.
130. Bowen LW. Fatal hyperpyrexia with antidepressant drugs. BMJ 1964;II:1465-6.
131. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
132. Ames D. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome - a possible link? [letter]. JAMA 1993;269:869.
133. Miyaoka H, Kanujima K. Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders? Int Clin Psychopharmacol 1995; 10:265-7.
134. Lane RM, Baldwin D, Preskorn SH. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995;9[suppl 2]:1-16.
135. Wiesel FA, Raaflaub J, Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol 1985;28:89-95.
136. Da Prada M, Kettler R, Keller HH, Haefely WE. Neurochemical effects in-vitro and in vivo of the antidepressant RO 11-1163, a specific and short-acting MAO-A inhibitor. Mod Probl Pharmacopsychiatry 1983;19:231-5.
137. Grimsley SR, Jann MW, Carter JG, Di Mello AP, Di Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50[suppl 1]:10-5.
138. Alderman J, Greenblatt DJ, Allison J, et al. Desipramine pharmacokinetics with the serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline. Neuropsychopharmacology 1994; 10[supp] 3, pt 2]:263S.
139. Baumann P, Bertschy G. Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs. Nord J Psychiatry 1993;47[suppl 30]:13-9.
140. Reynolds RD. Serotonergic drugs and the serotonin syndrome. Am Fam Physician 1994;49:1083-6.
141. Lappin RI, Auchincloss EL. Treatment of serotonin syndrome with cyproheptadine [letter]. N Engl J Med 1994;331:1021-2.
142. Sandyk R. L-Dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine [letter]. J Clin Psychopharmacol 1986;6:194-5.
143. Lieberman JA, Kane JM, Reife R. Neuromuscular effects of monoamine oxidase inhibitors. Adv Neurol 1986;43:231-49.
144. Guze BH, Baxter LR Jr. The serotonin syndrome: case responsive to propranolol [letter]. J Clin Psychopharmacol 1986;6:119-20.
145. Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide [letter]. Lancet 1994;343:475.
146. Grantham J, Neel W, Brown RW. Reversal of imipraminemonoamine oxidase inhibitor induced toxicity with chlorpromazine. J Kans Med Soc 1964;65:279-80.
147. Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 1987;42:760-3.
148. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994;24:68-76.
149. Gelenberg AJ. Polypharmacy in psychiatry: balancing caution with daring. CNS Drugs 1995;4:410-1.